Cdc25 activates maturation promoting factor (MPF) and promotes mitosis by removing the inhibitory phosphate from the Tyr-15 of Cdc2 in human cells. In this study, we searched the interacting protein(s) of human Cdc25C using the yeast two-hybrid screen and identi®ed proliferating cell nuclear antigen (PCNA) as an interacting partner of Cdc25C. The interaction between Cdc25C and PCNA was con®rmed in vitro and in vivo. Coimmunoprecipitation analyses using human T cell line, Jurkat, further revealed that Cdc25C interacted with PCNA transiently when cells began to enter mitosis. Immuno¯uorescence analysis also showed that Cdc25C and PCNA were transiently co-localized in the nucleus at the beginning of M phase. Together with the previous observations of the interaction between various cdc/ cyclin and PCNA, our ®ndings strongly suggested a potential role of PCNA at the G2 to M phase transition of cell cycle.
Introduction
The ®delity of genomic replication during cell division is ensured by checkpoint controls that prevent cell cycle progression when damage to DNA is encountered or key processes are not completed (Murray and Hunt, 1993; Hartwell and Kastan, 1994) . In mammalian cells, a major part of such regulation is achieved by a tumor suppressor protein p53 that has an essential role in the G1 checkpoint (Levine, 1997) . Although many malignant cells lack p53 function, as demonstrated by the absence of a G1 arrest after exposure to radiation or DNA-damaging anti-cancer drugs, yet these cells retain at G2 phase indicating the presence of another checkpoint mechanism, G2/M checkpoint, which is considered to endow malignant cells with the resistance to anti-cancer reagents (Yao et al., 1996; Suganuma et al., 1999) . The cell cycle G2/ M checkpoint control appears to involve a number of proteins such as Cdc2/Cyclin B, Wee1, Cdc25, 14-3-3, Cds1/Rad53 and Chk1 as well as DNA damage sensor proteins in a wide variety of eukaryotic cells (Nurse, 1997; Russell, 1998) .
Cdc25 plays a critical role in the G2/M checkpoint by controling the phosphorylation status of a major regulator Cdc2, a catalytic subunit of maturation promoting factor (MPF) (Parker and Piwnica-Worms, 1992; Russell and Nurse, 1986) . Cdc2 is subject to multiple levels of regulation including periodic association with cyclin B, reversible phosphorylation and intracellular compartmentation (Moreno et al., 1989; Gould and Nurse, 1989; Labbe et al., 1989; Pines and Hunter, 1989; Toyoshima et al., 1998) . Phosphorylation of Cdc2 occurs on three regulatory sites, Thr-14, Tyr-15, and Thr-161 (Gould and Nurse, 1989; Krek et al., 1992) . Wee1 kinase prevents MPF from executing G2 to M phase transition by phosphorylating Cdc2 at Thr-14 and Tyr-15 (Parker and Piwnica-Worms, 1992; Gould and Nurse, 1989) . It is known that Chk1 is activated by the damaged DNA in ®ssion yeast (Walworth et al., 1993; al-Khodairy et al., 1994; Walworth and Bernards, 1996) . It is also known that ®ssion yeast Cds1 (Boddy et al., 1998; Zeng et al., 1998; Lindsay et al., 1997) and budding yeast Rad (Weinert et al., 1994; Allen et al., 1994; Paulovich and Hartwell, 1995) are activated by the unreplicated DNA and presumably by the damaged DNA. It appears that there is redundancy between the function of Cds1 and Chk1, since abrogation of DNA damage checkpoint requires disruption of not only Chk1 but also Cds1 in ®ssion yeast (Boddy et al., 1998; Zeng et al., 1998; O'Connell et al., 1997) . The dual phosphatase Cdc25 triggers MPF by reversing the Wee1-mediated phosphorylation of Cdc2 (Parker and Piwnica-Worms, 1992; Russell and Nurse, 1986) . Both Chk1 and Cds1 can not only activate Wee1 (Boddy et al., 1998; O'Connell et al., 1997) but also directly suppress Cdc25 by phosphorylation at serine 216 (Zeng et al., 1998; Blasina et al., 1999; Lopez-Girona et al., 1999) , thus inhibiting the cell cycle progression by MPF. The phosphorylated Cdc25 is sequestrated in the cytoplasm by association with 14-3-3 (Lopez-Girona et al., 1999).
However, a small amount of Cdc25 was shown to reside in the nucleus at interphase and, moreover, most of Cdc25 stays in the nucleus throughout cell cycle phases in some cells Walworth et al., 1993) . These ®ndings suggest the presence of additional mechanisms that can prevent the premature activation of MFP by controlling Cdc25.
Proliferating cell nuclear antigen (PCNA), initially de®ned as an auxiliary protein for DNA polymerase d (pol d), has been shown to be essential for DNA replication and repair (Tan et al., 1986; Prelich et al., 1987; Prosperi, 1997) . PCNA associates with pol d and is involved in the maintenance of processive DNA synthesis at the leading strand of the replication fork as a sliding clamp. The role of PCNA in cell cycle regulation is suggested by the fact that pol d is involved not only in DNA replication but also in DNA repair and can be regulated by cell cycle proteins (Hindges and Hubscher, 1997) . In fact, PCNA was shown to interact with various cdk/cyclin complexes (Prosperi, 1997; Xiong et al., 1992; Szepesi et al., 1994) . Thus, PCNA may act as the platform for multiple protein ± protein interactions involved in replication, repair, recombination and cell cycle regulation. Interestingly, the PCNA protein level increased steadily through the whole cell cycle period and remained high at G2/M (Zeng et al., 1994) . These circumstantial evidences suggest that PCNA may also be involved in G2/M cell cycle control.
In this study we have identi®ed PCNA as a Cdc25C-binding partner during our screening of interacting proteins with Cdc25 by yeast two-hybrid system. We also demonstrate that Cdc25 interacts with PCNA at the beginning of M phase in human Jurkat T cell line.
Results
Identification of PCNA as a Cdc25C-interacting partner by yeast two-hybrid screen Yeast two-hybrid screening was performed to identify protein molecules interacting with human Cdc25. Since the full-length Cdc25C protein (amino acid 1 ± 473) fused with Gal4 DNA binding domain was transcriptionally active in the yeast, Y190 strain, the N-terminal portion of Cdc25C (amino acid 1 ± 301), devoid of such unwanted activity for the screening, was used as a bait. Among approximately two million recombinant clones screened, one clone containing the cDNA sequence of PCNA was identi®ed as the Cdc25C-binding partner. Figure 1 Interaction between Cdc25C and PCNA in yeast two-hybrid assay. Various Cdc25C deletion mutants were constructed using pAS2-1 vector and tested for the interaction with PCNA. Yeast Y190 cells were co-transformed with expression vectors encoding various Cdc25C proteins fused to Gal4 DNA-binding domain and pACT2-PCNA expressing PCNA fused to Gal4 activation domain. These transformants were streaked on selective medium lacking leucine and tryptophan, allowed to grow for 2 days at 308C and tested for b-galactosidase activity using X-gal colony ®lter assay as described previously (Yang et al., 1999; Tetsuka et al., 2000) . Hatched box (1 ± 40) indicates the minimal PCNA interaction region of Cdc25C obtained by this analysis.`+', positive for b-galactosidase activity;`itself', auto-activation of Lac Z reporter gene in Y190;`ND', not determined Thus, we further examined the speci®city of interaction by creating various Cdc25C deletion mutants and tested the interaction with PCNA by yeast two-hybrid system. As detected by the b-galactosidase activity in the yeast transformant, Y187 strain, an N-terminal 40 amino acid region of Cdc25C was found to be responsible for the interaction with PCNA (summarized in Figure 1 ).
Cdc25C interacts with PCNA in vitro
The interaction between Cdc25C and PCNA was examined by the in vitro`pull down' analysis using recombinant PCNA protein fused with glutathione-Stransferase (GST). The 35 S methionine-labeled fulllength Cdc25C was synthesized by in vitro transcription and translation, and incubated with either GST or GST ± PCNA. As demonstrated in Figure 2b , the fulllength Cdc25C interacted with GST ± PCNA but not with GST alone. We also synthesized the 35 S methionine-labeled EGFPCdc25C and EGFPCdc25C(90 ± 137) lacking the N-terminal region of Cdc25C (a negative control), and tested their interaction with PCNA. As shown in Figure 2c , EGFPCdc25C but not EGFPCdc25C(90 ± 137) bound to GST ± PCNA. Neither of these proteins bound to GST (not shown). These results have indicated that Cdc25C interacts with PCNA in vitro, supporting the results in Figure 1 .
Cdc25C transiently associates with PCNA in cells at the G2 to M phase transition To examine the association between Cdc25C and PCNA in live cells in vivo, we employed human T cell leukemia derived cell line Jurkat, which does not have wild type p53 and can not be arrested at G1 after DNA damage (Cheng and Haas, 1990; Kawabe et al., 1997) . As demonstrated in Figure 3a ,¯owcytometric analysis revealed that Jurkat cells arrested at G2 upon the DNA-damage induced by bleomycin. We also treated cells with OA, an inhibitor for protein phosphatase 2A and 1 and known to promote the cells to mitosis (M) upon DNA-damage (Gowdy et al., 1998) . Treatment of cells with OA alone could not eciently accumulate cells at G2/M phase (data not shown). In Figure 3b , we determined the phosphorylation status of the Tyr-15 of Cdc2 by successive immunoprecipitation and immunoblotting using antiCdc2 antibody and anti-phospho-tyrosine 15 Cdc2 antibody, respectively. We found that Tyr-15 of Cdc2 was phosphorylated by the bleomycin treatment ( Figure 3b , lane 2) and that the further treatment with OA decreased the tyrosine phosphorylation of Cdc2 ( Figure 3b , lane 3). These ®ndings, together with the result of¯ow cytometry (Figure 3a) , indicated that the cells treated with bleomycin and OA entered mitosis as reported (Gowdy et al., 1998) .
We also determined the phosphorylation status of Cdc25C, a key regulator of G2 checkpoint. The same ®lter of Figure 3b was probed with anti-Cdc25C antibody, which revealed that Cdc25C was hyperphosphorylated and appeared as a smear upon immunostaining of the cell lysate prepared from cells arrested at G2/M by the treatment with bleomycin and OA ( Figure 3c , lane 3). These results are in accordance with previous observations made by others in various species including human, hamster, frog and ®ssion yeast (Kawabe et al., 1997; Yamashita et al., 1990; Dunphy, 1992, 1996) . Taken together, these data indicated that Jurkat cells arrested at G2 phase were promoted to M phase by the additional treatment with OA in association with hyperphosphorylation of Cdc25C and dephosphorylation of Cdc2 at Tyr-15. In order to con®rm the results of Figures 1 and 2, we further explored whether Cdc25C is associated with PCNA at G2/M transition. In Figure 3d , Jurkat cells were arrested at G2 by the treatment with bleomycin and promoted to M phase by the additional treatment with OA. The cells were collected after 0, 15 and 30 min of OA treatment, lysed and immunoprecipitated with anti-PCNA antibody. The immunoprecipitates were resolved on 10% SDS ± PAGE and immunoblotted with anti-Cdc25C antibody. As demonstrated in Figure 3d , whereas Cdc25C was barely associated with PCNA in the G2 arrested cells (lane 1), the association between Cdc25C and PCNA became evident 15 min after the treatment with OA (lane 2), which was then declined after 30 min of OA treatment (lane 3).
Cell cycle-dependent interaction of Cdc25C with PCNA
We then tested if Cdc25C was associated with PCNA during the normal cell cycle. In Figure 4 , Jurkat cells were synchronized at early S phase by hydroxyurea and released to cell cycling. As shown in Figure 4a , owcytometric analysis revealed that a bulk of the cells Cells were treated with hydroxyurea (100 mg/ml) for 16 h and were released to cell cycling by washing and replacing the culture medium at time 0. Cells were then harvested every 2 h and subjected to the cell cycle analysis. (b) Presence of Cdc25C and Tyr-15-phosphorylated Cdc2 (Cdc2Y15P) in the PCNA immunoprecipitate. The cell lysate prepared at each time after the release was immunoprecipitated with anti-PCNA antibody, resolved by 10% SDS ± PAGE and immunoblotted with anti-Cdc25C, antiCdc2Y15P, and anti-PCNA antibodies. The similar experiments were performed at least three times and Cdc25C (always appeared as double band) was reproducibly detected in the PCNA immunoprecipitates at 6 ± 10 h (with 10 h at the highest level) after the release. The equal amount of proteins was applied in each lane. Note that the formation of Cdc25C/Cdc2Y15P/PCNA complex disappeared abruptly at 12 h after the release when majority of the cells entered M phase started to replicate DNA immediately after the release (Figure 4a , 2 ± 6 h). Most of the cells reached G2 phase 8 h after the release and stayed at G2/M for additional 4 h. In order to examine if Cdc25C interacts with PCNA during the G2-M transition, the lysate was prepared from these cells at each time point and was immunoprecipitated with anti-PCNA antibody. The PCNA protein complex was resolved on 10% SDS ± PAGE and examined for the presence of Cdc25C by immunoblotting. As shown in Figure 4b , Cdc25C was co-immunoprecipitated with PCNA and the interaction between Cdc25C and PCNA reached the maximum level at 10 h after the release. We also detected the interaction between Cdc25C and Cdc2Y15P (the Cdc2 phosphorylated at Tyr-15 and an inactive form for G2/ M progression), which was gradually increased after the release, reached maximum at 6 to 10 h and immediately disappeared (Figure 4b) . Thus, the formation of Cdc25C/Cdc2Y15P/PCNA appeared to occur concomitantly when cells entered G2. This complex formation was abruptly diminished when the majority of the cells passed to M phase at 12 h after the release.
Together with the observations in Figure 3 , in which the OA-induced phosphorylation of Cdc25C and its aberrant activation induced the dephosphorylation of Cdc2 at Tyr-15 and caused cells to enter M phase, these ®ndings indicate that the G2/M transition is correlated with the formation of Cdc25C/Cdc2Y15P/ PCNA complex and suggest that the dephosphorylation of Cdc2 by Cdc25C could eventually dissociate the complex and render cells to enter M phase.
Co-localization of Cdc25C and PCNA at the beginning of M phase
The localizations of Cdc25C and PCNA were investigated in Jurkat cells that were treated with bleomycin for 20 h followed by OA. As shown in Figure 5a (panels 1 ± 3; with bleomycin treatment alone), Cdc25C and PCNA were localized distinctively in the cytosol and the nucleus, respectively. However, after the cells were treated with OA for 15 min in addition to bleomycin, the staining pattern for both Cdc25C and PCNA became pancellular (Figure 5a , panels 4 ± 6). More prominently, when a cancer cell line, Panc1, was treated with bleomycin followed by OA after the transfection of pEGFPCdc25C, EGFPCdc25C appeared to be co-localized with chromatin (visualized by PI staining) at prophase (Figure 5b , arrow). PCNA is known to reside in chromatin at prophase (Tan et al., 1986; Prosperi, 1997) . Thus, Cdc25C was shown to be co-localized with PCNA when cells started to enter M phase, which was coincided with the appearance of protein complex involving Cdc25C and PCNA as detected by co-immunoprecipitation analysis (Figures 3 and 4) .
Abrogation of G2 checkpoint control by a mutant Cdc25C lacking the N-terminal PCNA interacting region
It was previously reported by Peng et al. (1997) that the Ser-216 of Cdc25C was responsible for the interaction with 14-3-3, a cytoplasmic anchoring protein, and that overexpression of mutant Cdc25C(S216A), lacking the interaction with 14-3-3, allowed cells to escape the G2 checkpoint arrest upon DNA damage. Thus, we ®rst examined if such mutant is sucient to abolish the DNA-damage-induced G2/M arrest. In Figure 6 , we have examined the eect of pEGFPCdc25C(S216A) overexpression and examined its ability to escape the G2 checkpoint control. As shown in Figure 6b (middle panel), expression of EGFPCdc25CS216A reduced the ability of cells to arrest at G2/M (from approximately 70 to 55%) as previously reported by others (Peng et al., 1997). However, deletion of the N-terminal 90 amino acids region of Cdc25C signi®cantly enhanced the ability of Cdc25CS216A to abrogate G2/M arrest after the DNA damage (Figure 6b , lower panel, in which only 38% of cells were found arrested at G2/M). These results strongly supported the importance of the PCNA binding of Cdc25C for its function.
Discussion
In this study, we have identi®ed PCNA as an interacting molecular partner of human Cdc25C by the yeast two-hybrid screen and con®rmed the interaction between Cdc25C and PCNA in vitro and in vivo. We have detected the formation of Cdc25C/ PCNA complex at the beginning of M phase when these two proteins were co-localized within the cell. We also detected the formation of Cdc25C/Cdc2Y15P/ PCNA complex at the G2/M transition (Figure 4) . Interestingly, this complex was abruptly dissociated when most cells entered M phase. Together with the observations in Figure 3 , in which the OA-induced phosphorylation of Cdc25C induced the dephosphorylation of Cdc2 at Tyr-15 and caused cells to enter M phase, these ®ndings suggest a possibility that the G2/ M transition is initiated by the formation of Cdc25C/ Cdc2Y15P/PCNA and that the dephosphorylation of Cdc2 (active form) by Cdc25C can eventually dissociate the complex and render cells to enter M phase. It was previously reported that PCNA could interact with various cdk/cyclin complexes (Prosperi, 1997; Xiong et al., 1992; Szepesi et al., 1994) in addition to the proteins involved in the DNA replication and repair such as DNA polymerase a, d, e, RFC, Fen1, XPG, RFA and p21 (Warbrick, 1998; Chen et al., 1996; Warbrick et al., 1997; Gary et al., 1997; Loor et al., 1997) . Thus, PCNA may provide a molecular platform for the interaction among various protein eectors involved in cell cycle regulation and DNA replication/repair. Although we detected the interaction between Cdc25C and PCNA in the yeast two-hybrid system where other human PCNA-interacting proteins were absent, this interaction in human cells appeared to be transient with maximum binding at the G2/M transition (Figures 3 and 4) . It is likely that PCNA may change the interacting partner during the cell cycle. Since XPG, Fen1 and p21 are known to be involved in the nucleotide excision repair (Chen et al., 1996; Warbrick et al., 1997; Gary et al., 1997) , Okazaki fragment processing at DNA replication (Loor et al., 1997) and prolongation of G2 delay (Medema et al., 1998) , respectively, it is assumed that the Cdc25C binding to PCNA may be hampered by these proteins when cells are replicating its genomic DNA, repairing the damaged DNA, or at the cell cycle arrest. Thus, it is possible that PCNA may have a role in coordinating the cell cycle progression program especially at G2 to M transition by selectively interacting with its molecular partners. In fact, a Cdc25C mutant, Cdc25C(S216A)deltaN, containing the substitution of its regulatory phosphorylation site and the deletion of the N-terminal PCNA-interacting region, strongly abolished the G2 checkpoint control as a dominantnegative mutant (Figure 6 ). Further studies are needed Figure 5 Co-localization of Cdc25C and PCNA. (a) Intracellular localization of Cdc25C and PCNA. Jurkat cells were treated with bleomycin for 20 h (1 ± 3) followed by OA for 15 min (4 ± 6). The same cells were stained with anti-Cdc25C antibody and FITClabeled goat anti-rabbit IgG (`2' and`5'), and anti-PCNA antibody plus rhodamine-labeled goat anti-mouse IgG (`3' and`6'). Nuclear staining was performed with Hoechst-33342 (`1' and`4'). (b) Localization of EGFPCdc25C. Human pancreatic cancer cell line, Panc11, was treated with bleomycin for 24 h (`1') and further treated with OA for 30 min (`2' and`3'). EGFPCdc25C was detected in chromatin in cells at anaphase (`2' and`3', indicated by an arrow) (in`3' chromatin was visualized in red by PI staining)
Interaction between Cdc25C and PCNA T Kawabe et al to examine whether this portion of Cdc25C is actually competing with Fen1, XPG or p21 for the interaction with PCNA. We found that Cdc25C and PCNA were co-localized in the cell at the beginning of M phase (Figure 5 ), which also supported the results of protein ± protein interaction in vivo. Nuclear translocation of Cdc25C is known to be initiated by the dissociation of its cytosolic anchoring protein 14-3-3 (Lopez-Girona et al., 1999) . Since it is known that Cdc25C does not activate Cdc2/Cyclin B in the cytoplasm, although 14-3-3 does not prevent the activation of Cdc25C to Cdc2/Cyclin B (Peng et al., 1997), it is possible that the interaction of Cdc25C with PCNA may be a prerequisite for further interaction with Cdc2/Cyclin B and its activation. As discussed above, the capability of PCNA to bind Cdc25C by itself may serve as a signal of the completion of DNA synthesis and repair. Once the interaction between Cdc2/Cyclin B complex and Cdc25 takes place, positive feedback loop involving polo-like kinase (Kumagai and Dunphy, 1996) would initiate the explosive reaction that eventually leads to mitosis, thus PCNA ± Cdc25C binding may no longer be required (as demonstrated in Figures 3 and 4) . It is also possible that the Cdc25C ± PCNA interaction may also serve as a fail-safe mechanism to prevent the premature onset of mitosis. We have recently demonstrated that the speci®c abrogation of Cdc25C activating kinase(s), Chk1 and Cds1, could sensitize cancer cells to the DNA-damage induced cell death (Suganuma et al., 1999) . Understanding of G2 checkpoint mechanism will not only decipher the elaborate cell cycle control system but also provide useful information for the development of novel cancer therapy.
Materials and methods

Construction of plasmids
Full-length Cdc25C cDNA (encoding 473 aa) was ampli®ed by PCR using a primer pair 25CFAS2 (5'-GCCGAATT-CATGTCTACGGAACTCTTCTCA-3') and 25CR (5'-CGAGGATCCTTATCATGGGCTCATGTCCTT-3') from pBSK1 that was kindly provided by P Russell (Sadhu et al., 1990) . The ampli®ed DNA fragment was cut by EcoRI and BamHI, and inserted into the compatible sites of pAS2-1 (Clontech), thus creating pAS2-1Cdc25C (1 ± 473). In order to construct pAS2-1Cdc25C (1 ± 301), the EcoRI and BglII digested fragment of the above PCR product was inserted into EcoRI and BamHI sites of pAS2-1. pAS2-1Cdc25C(378 ± 473) was constructed by removing the EcoRI fragment from pAS2-1Cdc25C(1 ± 473). Cdc25C(1 ± 173) was made by using a primer pair 25CFAS2 and DSal primer (5'-GCCGTCGACTCAGGAACAGTAGTAATGGGAC-3'), ampli®ed by PCR, cut with EcoRI and SalI, and inserted into compatible sites of pAS2-1. pAS2-1Cdc25C(1 ± 91) was constructed by removing the PstI fragment from pAS2-1Cdc25C (1 ± 473). pAS2-1Cdc25C (1 ± 40), pAS2-1Cdc25C (30 ± 67) and pAS2-1Cdc25C (60 ± 91) were constructed by using primer pairs 25CFAS2 and 25CP1 (5'-CAAGGAT-CCTCAGGTAAAGGAAGTGTCTCTC-3'), 25CP2 (5'-CA-AGAATTCAACCTGCTCCTGGAGAGAGAC-3') and 25CP3 (5'-CAAGGATCCTCAGGTTCCTCCAGACAAAATG-3'), and 25CP4 (5'-CAAGAATTCCTAAGCATTTTGTCTGGAGG-3') and 25CP5 (5'-CAAGGATCCTCATGCAGAAGTGGTAAG-CTG-3'), respectively. To create pEGFPCdc25C, full-length Cdc25C was ampli®ed from pBSK1 by PCR using a primer pair 25CF (5'-CCACTCGAGATGTCTACGGAACTCTTCT-CA-3') containing XhoI site and 25CR and the XhoI ± BamHI fragment was inserted into compatible sites of pEGFP-C1 (Clontech). pEGFPCdc25C(S216A) was constructed by substituting Ser-216 by Ala using a primer pair 5'-CGCTCCCCGGCG-ATGCCAGAGAACTTG-3' (S216F) and 5'-ATATAGGC-CACTTCTGCTCACCTTTGC-3' (S216AR), and ExSite PCRbased site-directed mutagenesis kit (Stratagene). The PstI ± BglII fragment was deleted from pEGFPCdc25C(S216A) to yield pEGFPCdc25C(S216A)deltaN. All plasmid constructions were con®rmed by the DNA sequencing with¯uorescence labeled dideoxy method using Genetic Analyzer 310 (ABI).
Yeast two-hybrid screen
Yeast two-hybrid screen was applied to identify genes that interact with Cdc25C. Plasmid pAS2-1Cdc25C(1 ± 301) was used as a bait since pAS2-1Cdc25C(1 ± 473), encoding fulllength Cdc25C in fusion with the Gal4 DNA-binding site, was positive by itself in the two-hybrid assay without the interacting partner containing the Gal4 activation domain. Human cDNA library from an osteosarcoma cell line for the yeast two-hybrid screening was obtained commercially (Matchmaker cDNA Library, Clontech). Screening was performed according to the supplier's protocol using yeast strain Y190 as described previously (Yang et al., 1999; Tetsuka et al., 2000; Uranishi et al., 2001) . For the subsequent two-hybrid assays to examine the protein ± protein interaction in the yeast, the pAS2-1 plasmids expressing various portions of Cdc25C (as described in Figure 1 ) were transfected into the yeast together with pACT2 ± PCNA, expressing PCNA fused to Gal4 activation domain, and detected the expression of b-galactosidase enzyme activity to con®rm the speci®c interaction.
In vitro pull-down analysis pGEX-PCNA, expressing the GST ± PCNA fusion protein in E. coli was kindly provided by M Nakanishi (Nakanishi et al., 1995) . E. coli DH5a were transformed either by pGEX4T1 (Amersham Pharmacia Biotech) or pGEX ± PCNA. The cells growing at logarithmic phase were incubated with 0.1 mM isopropyl b-D-thiogalactopyranoside (IPTG) for 2 h, harvested, lysed with a buer (50 mM TrisHCl (pH 8.0), 100 mM NaCl, 1% Triton-X100, protease inhibitor cocktail (Complete TM , Roche Diagnostics)), sonicated, centrifuged for clari®cation, and incubated with glutathione sepharose 4B beads (Amersham Pharmacia Biotech) for 1 h at 48C followed by washing ®ve times. In order to synthesize the radio-labeled proteins, in vitro transcription and translation was performed with a commercial kit (TNT quick coupled transcription/translation systems TM ; Promega) according to company's protocol with [ 35 S]methionine (Amersham Pharmacia Biotech). For the in vitro pull-down analysis, GST ± PCNA protein immobilized on 20 ml of glutathione sepharose beads was incubated with the radio-labeled Cdc25C proteins for 1 h at 48C with gentle mixing in buer A (100 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM DTT, 0.2% NP-40, 10 mM NaF, 10 mM Na 3 VO 4 , 1 mM okadaic acid). The beads were then washed ®ve times with 1 ml each of buer A. The bound radio-labeled Cdc25C proteins were eluted with 5 ml of Laemmli SDS ± PAGE sample buer, boiled for 2 min, and resolved by 10% SDS ± PAGE as described previously (Yang et al., 1999) .
Cell culture and synchronization
A human T cell leukemia derived cell line, Jurkat, was cultured in RPMI 1640 (Sigma) supplemented with 10% fetal bovine serum (IBL) at 378C/5% CO 2 . A human pancreatic epitheloid carcinoma derived cell line, Panc1 and a human kidney derived cell line, 293, were cultured in Dulbecco's modi®ed Eagle's medium supplemented with 10% fetal bovine serum (IBL) at 378C/5% CO 2 . For Panc1 culture, 4 mM l-glucose (Sigma) and 1 mM sodium pyruvate (GIBCO ± BRL) were further supplemented. Jurkat cells were cultured for 23 h in the presence of 100 mg/ml hydroxyurea (Sigma) and released to cycle by washing with culture media extensively.
Cell cycle analysis and the treatments with bleomycin and okadaic acid
The cell cycle pattern was examined by¯ow cytometry using FACScan (Beckton Dickinson) and CELL Quest (Beckton Dickinson) software as described (Suganuma et al., 1999; Kajino et al., 2000) . Brie¯y, 2610 6 cells were washed twice with cold PBS, resuspended in 300 ml Krishan's solution (0.1% Sodium Citrate, 50 mg/ml propidium iodide (PI), 20 mg/ml RNase A, 0.5% NP-40). Bleomycin and okadaic acid (OA) were purchased from Wako Chemical Co. Jurkat cells were treated with 10 mg/ml freshly prepared bleomycin for 23 h before the addition of 1.0 mM OA. In order to examine the eects of EGFPCdc25C(S216A) and EGFPCdc25C(S216A)-deltaN, 219 cells (2610 6 ) were either transfected by respective plasmid or mock transfected, cultured for 24 h, treated with bleomycin (10 mg/ml) for additional 24 h, and harvested. The cells were washed twice with cold PBS and ®xed with 70% cold ethanol for 20 min. After washing with 0.1% Tween 20 in PBS, the cells were stained with anti-GFP antibody (Molecular Probes) and FITC-labeled goat anti-rabbit antibody (ICN Pharmaceuticals).
Co-immunoprecipitation and immunoblotting
Twenty million Jurkat cells were lysed in 1 ml of buer A and centrifuged. Cleared lysate was sequentially incubated at 48C with 4 ml of rabbit polyclonal anti-Cdc2 antibody (New England Biolabs) and protein G sepharose (Amersham Pharmacia Biotech) for 1.5 and 1 h, respectively. After extensive wash, the immunoprecipitates were separated in 12% SDS ± PAGE and immunoblotted for anti-Cdc2 phospho-tyrosine 15 antibody (New England Biolabs) with horseradish peroxidase labeled anti-rabbit IgG (Amersham Pharmacia Biotech) and visualized with SuperSignal TM (Pierce). To detect the hyperphosphorylated Cdc25C, Cdc25C was immunoprecipitated, separated by 12% SDS ± PAGE, and immunoblotted with anti-Cdc25C antibody (a generous gift from H Piwnica-Worms; Peng et al., 1997) and horseradish peroxidase-labeled anti-mouse IgG (Amersham Pharmacia Biotech). To detect the interaction between PCNA and Cdc25C, PCNA was immunoprecipitated with 5 ml of anti-PCNA antibody (Santa Cruz Biotechnology), separated by 10% SDS ± PAGE, and immunoblotted with anti-Cdc25C (Santa Cruz Biotechnology) and horseradish peroxidase-labeled anti-rabbit IgG (Amersham Pharmacia Biotech) as described previously (Kajino et al., 2000; Uranishi et al., 2001) . The immunoprecipitated PCNA was detected with anti-PCNA (Santa Cruz Biotechnology) and horseradish peroxidase labeled anti-mouse IgG (Amersham Pharmacia Biotech).
Immunofluorescent microscopy
Jurkat cells were treated with 10 mg/ml bleomycin for 20 h. The cells were ®xed in acetone/ethanol (1 : 1) for 2 min at room temperature after the treatment with or without 1 mM OA (Sigma) for 15 min. Then, they were washed with PBS and stained either by Hoechst33258 (Hoechst), anti-Cdc25 antibody (Santa Cruz Biotechnology) plus FITC-labeled goat anti-rabbit IgG (ICN pharmaceuticals), or anti-PCNA antibody (Santa Cruz Biotechnology) plus rhodamine-labeled goat anti-mouse IgG (Calbiochem). Panc1 cells were transfected with pEGFPCdc25C by electroporation (BTX electroporater, 200 V, 800 mF, 4 mm space gap cubette; Bio Medical Equipment) and treated with 10 mg/ml bleomycin after the transfection. The cells were harvested 24 h after the addition of bleomycin with or without 1 mM OA treatment for 30 min. The cells were washed twice with PBS, ®xed with 4% paraformaldehyde for 20 min at room temperature, and permeated by incubating 6 min in PBS with 0.2% gelatin and 0.5% Triton X-100 for staining. Anity-puri®ed anti-GFP antibody (Molecular Probes) and FITC-labeled goat antirabbit antibody (ICN Pharmaceuticals) was employed to stain GFP. PI was used to identify the chromatin. Thē uorescent microscopicy was performed with a laser confocal microscopy (BX50, Olympus).
Abbreviations MPF, maturation promoting factor; PCNA, proliferating cell nuclear antigen; pol d, DNA polemerase d; M, mitosis; IPTG, isopropyl b-D-thiogalactopyranoside; PI, propidium iodide; GST, glutathione-S-transferase; OA, okadaic acid.
